Clinical Trials Logo

Traumatic Hemorrhage clinical trials

View clinical trials related to Traumatic Hemorrhage.

Filter by:
  • None
  • Page 1

NCT ID: NCT05504733 Completed - Clinical trials for Traumatic Hemorrhage

LAVA TQ Doppler Functionality Study

Start date: May 9, 2022
Phase: N/A
Study type: Interventional

This is a single-blinded, randomized clinical trial to determine if the Layperson Audiovisual Assist tourniquet's (LAVA TQ) ability to occlude arterial blood flow is non-inferior to that of the Combat Application Tourniquet (CAT).

NCT ID: NCT04534751 Recruiting - Coagulopathy Clinical Trials

Factor In the Initial Resuscitation of Severe Trauma 2 Patients

FiiRST-2
Start date: April 1, 2021
Phase: Phase 4
Study type: Interventional

Injury is the leading cause of death for people between the ages of 1-44. This is especially true in trauma patients who have bleeding complications. Acute trauma coagulopathy (ATC) is associated with high transfusion requirements, longer ICU stays, and a greater incidence of multi-organ dysfunction. The cause of coagulopathy is multi-factorial. One major driver is acquired fibrinogen deficiency (hypofibrinogenemia). Fibrinogen is critical in clot formation and enhances platelet aggregation. Due to the body's limited reserve, it is the first clotting factor to fall to critical levels during life-threatening bleeding. This can impair coagulation and increases bleeding complications. There are two primary options available for fibrinogen supplementation: - Cryoprecipitate- North American standard - Fibrinogen Concentrate (FC)- European standard Consumption of coagulation factors, including fibrinogen, is another important component of ATC. To replenish these depleted coagulation factors and improve thrombin generation, two therapies are available: - Frozen Plasma (FP)- North American standard - Prothrombin Complex Concentrate (PCC)- European standard Strategies for hemorrhage and coagulopathy treatment have changed significantly over the last decade. Prompt hemorrhage control, along with targeted coagulation factor replacement, are emerging as key components of trauma care. Currently, the initiation of a massive hemorrhage protocol (MHP) results in red blood cells (RBCs) and FP transfusions in a 1:1 or 2:1 ratio. Clotting factors are replaced via FP administration. Fibrinogen supplementation is administration after lab verification or at the clinician's discretion. MHP continues until the rate of hemorrhage is under control. FC and PCC have several important advantages over cryoprecipitate and FP but there is a scarcity of data regarding their efficacy and safety of their use in hemorrhaging trauma patients. The FiiRST-2 study aims to understand if early use of FC and PCC in trauma patients at risk of massive hemorrhage will lead to superior patient outcomes. This trial will also provide safety data on early administration of FC and PCC as a first-line hemostatic therapy in trauma care, and its impact on hemostatic and other clinical endpoints.

NCT ID: NCT03780894 Completed - Polytrauma Clinical Trials

Transfusion of Red Blood Cells, Tranexamic Acid and Fibrinogen Concentrate for Severe Trauma Hemorrhage at Pre-hospital Phase of Care.

PRETIC
Start date: November 21, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single-center, not-randomized, open-label, controlled pilot clinical trial. This study compares presence of Trauma Induced Coagulopathy (TIC) and acute traumatic hemorrhage treatment at pre-hospital phase of care with red blood cells (RBC), Tranexamic acid (TXA) and Fibrinogen Concentrate (FC) with the current treatment based on the administration of Crystalloids and TXA.

NCT ID: NCT03479112 Completed - Clinical trials for Traumatic Hemorrhage

Determine the Most Effective Intervention for Hemorrhage Control Readiness for Laypersons: The PATTS Trial

PATTS
Start date: May 22, 2017
Phase: N/A
Study type: Interventional

This is a randomized controlled study evaluating the ability of laypersons to correctly apply a tourniquet using different instructional methods. There are four arms being evaluated: flashcards, audio-kit with visual aids, formal in person Bleeding Control Basic (B-Con) course, and a control arm. All participants will then undergo B-Con training at the end of each session and then participants will be evaluated within a 3-6 month time period to evaluate their retention of knowledge and skills taught by the B-Con course.

NCT ID: NCT02086500 Completed - Clinical trials for Traumatic Hemorrhage

Study of Tranexamic Acid During Air and Ground Medical Prehospital Transport Trial (STAAMP Trial)

STAAMP
Start date: July 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if 1 gram of prehospital tranexamic acid given during emergency medical transport to a level 1 trauma center in patients at risk of hemorrhage is associated with lower 30 day mortality.

NCT ID: NCT00328133 Completed - Hemorrhagic Shock Clinical Trials

The Use of rFVIIa in Trauma Patients: A Multi-Center Case Registry

Start date: June 2006
Phase: N/A
Study type: Observational

Trauma surgeons throughout the US have begun using recombinant activated factor VII (rFVIIa) to control severe hemorrhage following injury when traditional measures have failed. Despite promising results from several small studies, there remain several unanswered questions regarding the use of this relatively expensive product in injured patients including: - The timing of administration - Selection of appropriate patients who are most likely to benefit - The effective dose in injured patients - The potential need for repeated dosing - The need for administration of platelets and correction of acidosis prior to administering the first dose - The risks associated with the use of rFVIIa including venous and/or arterial thrombosis - The potential for rFVIIa to cause or aggravate post-injury organ failure and/or infectious complications - An analysis of cost versus benefit The purpose of this study is to collect a large sample of patients from multiple institutions in order to address the issues listed above. To this end, the Western Trauma Association Foundation is sponsoring a multi-center case registry for patients receiving rFVIIa for treatment of uncontrolled hemorrhage.